AzTrials
AzTrials

InfluenzaRESPIFLUNCT01271842

Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study

An observational study of Influenza and Pneumonia, Viral, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Influenza A (H1N1) v2009 infection was responsible throughout the world of viral pneumonia and severe pulmonary edema requiring rescue therapeutics such as extracorporeal oxygenation. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Influenza, Pneumonia, Viral, Pulmonary Fibrosis
How many people
38 participants
Where
1 siteFrance
Study dates
Oct 2010to 2 Oct 2011
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Two groups of survivors of severe acute respiratory distress syndrome due to influenza A H1N1 infection will be recruited; the first required extracorporeal oxygenation at the time of viral infection, and the second did not require extracorporeal oxygenation at the time of viral infection. Patients will be recruited at least 9 months after ICU discharge. Eighteen case patients matching inclusion and non-inclusion criteria were selected from our national registry, and 32 controls (with inclusion and exclusion criteria) were matched on age, sex, and body mass index.

Who may be able to join

  • Patients from 18 to 65 year-old
  • Survivors of ARDS due to influenza A (H1N1) v2009 infection developed during the winter 2009-2010
  • Influenza A (H1N1) infection confirmed by RT-PCR
  • Written consent
  • Need or not for extra corporeal lung oxygenation

Who cannot join

  • Pre existing pulmonary disease
  • Asthma
  • Diabetes mellitus
  • Immunodepression
  • Cancer
  • Severe obesity (BMI >35 kg/m²)
Show all 12Show fewer
  • Neuromuscular disease
  • Pre existing cardiac disease
  • Chronic renal failure
  • Liver failure
  • Stroke
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU Pitié-Salpêtrière

    Paris, 75013

Other trials in France

About this study

Influenza A (H1N1) v2009 infection was responsible throughout the world of viral pneumonia and severe pulmonary edema requiring rescue therapeutics such as extracorporeal oxygenation. To date, no data exist on the outcome of patients having developed acute respiratory distress syndrome (ARDS) due to influenza A (H1N1) v2009, and in particular in patients with very severe lung injury requiring extracorporeal oxygenation. Although data exist on long-term outcome of survivors of ARDS, the patients included in the observational studies were heterogeneous with various underlying disease. Moreover, no study compared the outcome of survivors of ARDS according to the need or not of extracorporeal oxygenation. We therefore conducted this prospective case-control study to compare the long term pulmonary and extra pulmonary function in 2 groups of patients, one with severe ARDS due to H1N1 requiring extracorporeal oxygenation (case), and the second with ARDS due to H1N1 but without need for extracorporeal oxygenation (control). Eighteen case patients with inclusion and without non-inclusion criteria were selected from our national registry, and 32 controls (with inclusion and exclusion criteria) were matched on age, sex, and body mass index. All 48 patients will be contacted and asked to participate. Patients will be evaluate at least 9 months after ICU discharge, looking for health-related quality of life, measured by the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36), post traumatic stress disorder, assessed by the Impact of Event Scale Anxiety, and depression, assessed by the Hospital and Depression Score. Pulmonary function testing, including VO2 max test on a static bike will be performed. Muscle weakness will be clinically evaluated by the medical council research (MRC) test, with an additional electromyography if the result of the test was <48/60. A CT-scan will be performed, looking for lung abnormalities (fibrosis...). Albumin and prealbumin will be measured to evaluate the nutritional status.

Primary outcome measurement is carbon monoxide diffusion capacity. The primary hypothesis is that patients with extracorporeal oxygenation will have a carbon monoxide diffusion capacity lower than patients without extracorporeal oxygenation (15% difference between groups). Inclusion of 13 patients in the case group and 26 patients in the control group will allow testing this hypothesis with a statistical power of 80% (standard deviation 15%). Secondary outcome measures will be the quality of life, the presence or not of post-traumatic stress disorders, of anxiety and/or depression, the results of pulmonary function testing, of the CT-scan, and of muscle testing. All results will be compared in patients with and without extracorporeal oxygenation.

Medical subject headings
Influenza, Human, Pneumonia, Viral, Pulmonary Fibrosis, Combat Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01271842
Study groupRoleWhat they receive
Extra corporeal oxygenationSurvivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
No extracorporeal oxygenationSurvivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Carbon monoxide diffusion capacity

    Measured: At least 9 months after ICU discharge

Secondary outcomes (7)
  1. Health-related quality of life

    Measured: At least 9 months after ICU discharge

  2. Pulmonary function testing

    Measured: At least 9 months after ICU discharge

  3. Post traumatic stress disorder

    Measured: At least 9 months after ICU discharge

  4. Anxiety and depression

    Measured: At least 9 months after ICU discharge

  5. Muscle weakness

    Measured: At least 9 months after ICU discharge

  6. Lung abnormalities on CT scan

    Measured: At least 9 months after ICU discharge

  7. Alveoli-arterial gradient of oxygen during effort

    Measured: At least 9 months after ICU discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2011 (estimated)
  2. Study startOct 2010
  3. Primary completion2 Oct 2011
  4. Study completion2 Oct 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01271842
Sponsor's protocol ID
C10-26
Other IDs
2010-A00741-38
Acronym
RESPIFLU
Status last verified
Dec 2012
First submitted
6 Jan 2011
Last updated
7 Oct 2025
Results posted
No
Data monitoring committee
No

Publications

  • Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J; REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep;142(3):583-592. doi: 10.1378/chest.11-2196.

    PubMed 22948576

Questions about this trial

What is this clinical trial studying?

An observational study of Influenza and Pneumonia, Viral, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Carbon monoxide diffusion capacity (time frame: At least 9 months after ICU discharge). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01271842, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in